StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)

StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Rating) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other equities analysts have also recently commented on the stock. HC Wainwright cut shares of Genocea Biosciences from a “buy” rating to a “neutral” rating in a research note on Friday, April 29th. Robert W. Baird dropped their price objective on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th. Finally, Stifel Nicolaus cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, April 29th.

NASDAQ GNCA opened at $0.17 on Friday. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.08. The company has a market cap of $9.87 million, a P/E ratio of -0.28 and a beta of 1.90. Genocea Biosciences has a 1 year low of $0.16 and a 1 year high of $2.68.

Genocea Biosciences (NASDAQ:GNCAGet Rating) last released its earnings results on Thursday, March 10th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). During the same quarter in the previous year, the business posted ($0.18) EPS. Equities research analysts forecast that Genocea Biosciences will post -0.6 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Genocea Biosciences by 197.5% during the 2nd quarter. Morgan Stanley now owns 16,504 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,957 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Genocea Biosciences by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 185,942 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 6,228 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Genocea Biosciences by 6.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,652,974 shares of the biotechnology company’s stock worth $5,094,000 after purchasing an additional 152,974 shares in the last quarter. Commodore Capital LP increased its position in shares of Genocea Biosciences by 5.1% during the 3rd quarter. Commodore Capital LP now owns 3,079,756 shares of the biotechnology company’s stock worth $5,913,000 after purchasing an additional 150,309 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Genocea Biosciences by 31.9% during the 3rd quarter. Millennium Management LLC now owns 377,345 shares of the biotechnology company’s stock worth $725,000 after purchasing an additional 91,304 shares in the last quarter. Institutional investors own 59.25% of the company’s stock.

About Genocea Biosciences (Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Further Reading

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.